TOTAL: $182.65M

Year to Date: $649.70M

Company (Symbol)#*

Partner (Country)

Amt. (M)

Triggering Event

Details (Date)

Acadia Pharmaceuticals Inc. (ACAD)

Allergan Inc. (NYSE:AGN)


Milestone payment

Tied to the initiation of an exploratory glaucoma trial (7/16)

Amorfix Life Sciences Ltd. (Canada; CDNX:AMF)

Biogen Idec Inc. (BIIB)


Investment milestone

Biogen Idec will subscribe for 91,445 shares at C$1.76 ($1.69) per share for gross proceeds of $150,000; the investment allows Biogen Idec to retain its exclusive worldwide option to license Amorfix's drug candidates for amyotrophic lateral sclerosis (7/23)

Biota Holdings Ltd. (Australia; ASX:BTA)

MedImmune Inc. (unit of AstraZeneca plc; UK; LSE:MDI)


Milestone payment

For the start of a Phase Ia trial of BTA9881 for respiratory syncytial virus (7/17)

ChemoCentryx Inc.*

GlaxoSmithKline plc (UK)


Milestone payment

For progress in their small-molecule CCR1 discovery and development program; it was triggered by the acceptance of ChemoCentryx's orally bioavailable small molecule, CCX354, as a candidate for full development (7/24)

Durect Corp. (DRRX)

Nycomed A/S (Denmark)


Milestone payment

For Phase IIb data showing statistically significant reductions in pain with Posidur when treating patients undergoing inguinal hernia repair (7/17)

Galapagos NV (Belgium; LSE:GLPG)

Boehringer Ingelheim GmbH (Germany)


Milestone payment

Galapagos said its BioFocus DPI service division received the payment in relation to its autoimmune discovery research collaboration with Boehringer Ingelheim (7/20)

ImmunoGen Inc. (IMGN)

Genentech Inc. (NYSE:DNA)


Milestone payment

For the initiation of a Phase II breast cancer trial with trastuzumab-DM1 (7/31)

InterMune Inc. (ITMN)

F. Hoffmann-La Roche Ltd. (Switzerland)


Milestone payment

InterMune earned the milestone when Roche submitted an amended clinical trial authorization in Europe for ITMN-191 in chronic hepatitis C patients (7/25)

Medarex Inc. (MEDX)

Novartis Pharma AG (Switzerland)


Milestone payment

For advancing ACZ885 into a Phase III trial (7/18)

Neuroptix Corp.*

Merck & Co. Inc.


Milestone payment

Related to its Alzheimer's disease diagnostic collaboration (7/16)

NicOx SA (France; FSE:NXO)

Merck & Co. Inc.


Milestone payment

For the initiation of the first in a series of planned clinical trials for the lead candidate from an agreement to develop nitric oxide-donating antihypertensive agents using NicOx's technology (7/16)

Pharmacopeia Drug Discovery Inc. (PCOP)

GlaxoSmithKline plc (UK)


Milestone payment

For the identification of a lead compound for advancement six months ahead of the original schedule; the compound is being evaluated as a treatment for inflammatory pain, and will now enter lead optimization (7/17)

Santarus Inc. (SNTS)

Schering-Plough Healthcare Products Inc. (division of Schering-Plough Corp.)


Milestone payment

For clinical development progress on a license agreement for proton pump inhibitor products using Santarus' PPI technology (7/20)

Vivus Inc. (VVUS)

KV Pharmaceutical Co.


Milestone payment

Vivus won FDA approval of Evamist to treat severe vasomotor symptoms due to menopause, triggering the milestone payments (7/30)


# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Private company.

Currency conversions are based on exchange rates at the time of the deal.

ND = Not disclosed.

ASX = Australia Stock Exchange; CDNX = Canadian Venture Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange.